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ess: shaledj@cardiff.acSummary Background: Chronic obstructive pulmonary disease (COPD) is common.
Diagnosis should include objective evidence of airways obstruction and spirometry is
recommended in guidelines and the general medical services contract in the UK. We
assessed the impact of spirometry in general practice.
Method: We determined by questionnaire the availability, staff training, use and
the interpretation results of spirometry in 72% of general practices in Wales. We
reviewed the diagnosis of COPD previously made in two general practices without
spirometry.
Results: Most practices had a spirometer (82.4%) and used it (85.6%). Confidence
in use and interpretation of results varied widely: 58.1% were confident in use and
33.8% confident in interpretation. Spirometry was performed more often if confident
in use and interpretation (both Po0:001) and was related to greater training periods
(Po0:001). Spirometric confirmation of COPD varied widely (0–100%, median 37%).
Of the 125 patients previously diagnosed with COPD 61 had spirometric confirmation,
while 25 had reversible obstruction (range 210–800mls), 34 had normal and 5 had
restrictive spirometry.
Conclusion: Despite incentives to perform spirometry in general practice, lack of
adequate training in use and interpretation suggests use is confounded and the
diagnosis of COPD is likely to be made on imprecise clinical grounds.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
ndation, GlaxoSmithKline,
+44 29 20716948; fax:
.uk (D.J. Shale).Introduction
Chronic obstructive pulmonary disease (COPD) is a
major cause of morbidity and a leading cause ofed.
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increasing.1,2 It presents a major challenge to
healthcare provision with an overall prevalence of
10% in the community, rising to 26% in patients aged
over 45 years for chronic airflow limitation.3–5 This
is COPD identified in surveys, but it is likely that
only 25–50% of such patients are known to their
general practitioners.4–8 The reasons for under
diagnosis include under reporting of symptoms by
patients, their incorporation in asthma lists and the
limited use of spirometry in general practice.3,9–14
There has been added impetus to obtaining a
correct diagnosis of COPD, particularly in primary
care, with the Global initiative for Chronic Ob-
structive Lung Disease (GOLD),9 the British Thoracic
Society (BTS) management guidelines15 and the
National Institute for Clinical Excellence (NICE)
guidelines in the United Kingdom.16 The new
service contract for general practitioners in the
United Kingdom includes the creation of COPD
registers and the use of spirometry as an objective
component of diagnosis and monitoring of disease
progression for which practices will be rewarded
financially.17
In general practice, symptoms, examination and
smoking history have been used to diagnose COPD.
Diagnosis made on this basis may be inaccurate due
to the range of presentations from asymptomatic
(whilst significant lung impairment on objective
testing) through to multiple non-specific symptoms
such as shortness of breath, cough, wheeze and
sputum production, which overlap with other
respiratory disorders, not least asthma.18,19 As
COPD is a mainly irreversible and progressive
disease with serious systemic complications20–22
and a sub-clinical phase to these problems, precise
and early diagnosis is essential.9
The recommended diagnosis of COPD rests on an
appropriate history and objective confirmation of
airways obstruction.9,15 A peak expiratory flow
(PEF) of o80% predicted will detect over 90% of
patients with COPD, though the specificity is low at
82%.23 Spirometry is widely considered necessary to
identify patients precisely and detects milder
degrees of airways obstruction than PEF. Addition-
ally severity can be defined, indicating those most
at risk of exacerbations, persistent hypoxaemia or
corpulmonale.24–26 Determination of the presence
or absence of reversibility of airways obstruction to
bronchodilator treatment has been recommended,
though there is controversy over reliance on this
test,27–29 which is currently in the BTS guidelines15
and a requisite for diagnosis in the new contract for
general practice.17
We undertook a questionnaire-based survey dur-
ing the latter six months of 2003 to determine thelevel and acceptability of spirometry usage in
general practice in the Welsh health region in the
UK. Additionally, to determine the impact of
spirometry on the diagnosis of COPD in general
practice we studied patients with previous non-
spirometry supported diagnosis of COPD.Method
Questionnaire
A questionnaire (Appendix A) was sent to 371 (72%)
randomly selected general practices of the 518 in
Wales.30 The questionnaire was directed to the
main spirometer user or the respiratory medical
professional, with a duplicate sent to practices not
responding to the initial request. Questions related
to: the availability of spirometry; access to local
lung function without consultant physician referral;
confidence in use (including calibration); interpre-
tation of results; the type and length of training, as
well as the number of their registered COPD
patients investigated with spirometry.
Patients with previously diagnosed COPD
We studied 125 patients drawn from two local
general practices, reflecting the population profile
of Cardiff. They were selected on the basis of a
diagnosis of COPD made within the practice (based
on UK national codes READ: H3, H36-H3y, H3z and
H32), based on history and examination without
spirometry. Patients were studied when clinically
stable, defined as no requirements for antibiotics
or corticosteroids and no change in respiratory
symptoms beyond normal day to day variation in
the last month. Patients refrained from using short
acting inhaled bronchodilator treatment for 6 h and
all other inhaled therapy for the preceding 12 h.15
Spirometry was carried out and interpreted by
one of three experienced users (CB, AAI, TAF) using
Vitalograph alpha (Bucks, UK) or Microlab 3300
(Micromedical, UK) spirometers. Both machines
were calibrated and serviced according to the
manufacturer’s direction and the same machine
was used for an individual patient.
Three acceptable forced manoeuvres were per-
formed with consistent verbal encouragement to
obtain at least two recordings with both the forced
expiratory volume in the first second (FEV1) and
forced vital capacity (FVC) within 5% or 0.1 l of
each other.31 The ratio FEV1/FVC was recorded.
Patients with airways obstruction (FEV1/FVCo
0.7, FEV1o80% predicted) underwent reversibility
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spacer with tidal breathing.9,15 Spirometry was
repeated 15min later. Reversibility was classed
as an increase in FEV1 of 15% and 200mls.
15
Patients with non-reversible airways obstruction
were classified as COPD.15 Patients without airways
obstruction or with reversible airways obstruc-
tion were referred back to their GP for further
management.
Statistical analysis
Descriptive statistics and analysis were performed
using Statistics Package for Social Sciences (SPSS)
version 11.0. Differences between groups were
determined by Chi-square or Mann–Whitney U
tests.Figure 1 Confidence in performing spirometry (n ¼ 121)
represents the median.Results
Questionnaire
The response rate was 61.6%, 227 of the 371
practices contacted, with coverage across the
area. Each practice was asked the size of the
population they covered. From 214 practices
reporting, the estimated population served was
1,415,647 individuals (approximately 49% of the
Welsh population32).
Spirometry
Of the 227 responding practices, 187 (82.4%)
possessed a spirometer of which 160 reported
usage. Of the 27 practices not reporting use, 11
never used; 12 had recently purchased their
machine and four practices did not answer the
question. Of the 160 performing spirometry, 35
(21.9%) used it for diagnosis in every suspected case
of COPD with a further 54 (33.8%) using it often;
while 71 (44.4%) used it sometimes or rarely.
Spirometry was carried out in 111 of the 160
practices by the practice nurse or nurse practi-
tioner; in 15 by the general practitioner; in 34 by
both general practitioner and nurse.
Level of confidence with the use of a spirometer
and interpretation of results
Of the 160 practices performing spirometry, 93
(58.1%) were confident using the spirometer
while the remaining 67 reported less confidence.
Of those using the spirometer in every case of
COPD diagnosed, 28 of 35 (80%) were confident
with use, whilst of the 54 using the spirometer
often, 40 (74%) were confident. Spirometry wasperformed more often in practices confident in
use, compared with those with less confidence
(Po0:001).
Only 54 (33.8%) of practices reported satisfaction
with interpretation of results, while 104 practices
reported limited or no confidence (two no answer).
Where spirometry was used with every case of
COPD, 62% practices were confident with inter-
pretation of the results. Of the 54 practices
reporting often use, 52% were confident with
interpretation. Again, spirometry was performed
more often in those who were confident in
interpretation of the result, compared with those
with less confidence (Po0:001).Training in the use of spirometry
Of the practices performing spirometry, 121 re-
ported median training in use of the equipment of
4, range 0–30 h of which 10 reported no training.
However, the median training for those confident in
using their spirometer (n ¼ 69) was 6 range 0–30 h;
limited confidence (n ¼ 44) 3, range 0–20 h; not
confident (n ¼ 8) 1, range 0–14 h, Po0:001 (Fig. 1).
For practices with a spirometer but not using it (8/
11 responses) median training was 0.5 (range
0–4) h.Training in the interpretation of spirometry
The median period of training in interpretation of
results for the 90 practices responding and using
spirometry was 2, range 0–30 h of which 13
reported no training. Of those confident with
interpretation, (n ¼ 24) the median training was
4, range 1–15 h; limited confidence (n ¼ 53)
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Figure 3 Results of spirometry in 125 patients previously
diagnosed as COPD on the basis of history and examina-
tion.Figure 2 Confidence in interpreting spirometry results
(n ¼ 90) represents the median.
C.E. Bolton et al.4962,0–30 h; not confident (n ¼ 13) 0.6, 0–3 h,
Po0:001; Fig. 2. Training in interpretation for those
who possessed a spirometer but did not use it (6/11
responses) was median 0 (range 0–2.5) h.
There was no detailed information on how
training was delivered or assessed. The provision
of spirometry training was varied, encompassing
specific spirometry courses, hospital based and
pharmaceutical company based, as well as one-to-
one tuition.
Use of spirometry to confirm diagnosis
Spirometric confirmation of COPD ranged from 0%
to 100%, with a median of 37% in the 87
respondents giving this information. No details
were asked regarding reversibility. The percentage
of patients with COPD confirmed by spirometry
within practices confident with use was median
50.5%, n ¼ 50; P ¼ 0:155 and interpreting median
54.7%, n ¼ 34; P ¼ 0:022 compared with those with
less confidence (confirmation median 29.4%, n ¼ 25
and 30.7%, n ¼ 39; respectively).
Practices without a spirometer
Of the 40 practices without a spirometer, three had
open access to hospital lung function, 31 did not
and six gave no answer. Only one practice reported
using hospital lung function in every case of COPD
and two used it sometimes.
Patients with previously diagnosed COPD
Of the 125 patients, 62 were female and 63 male;
mean age 64.3 years, range 43–85. History of atopy,
family history of asthma and triggers did notseparate out into the group who consequently
reversed. Six patients had never smoked, the rest
had a median pack year history of 40, range
1.5–120.
Airways obstruction was found in 86 patients of
which 61 did not reverse and according to the
guidelines were classed as COPD14 (Fig. 3). Of these
patients 13 had severe; 24 moderate; and 24 mild
disease. This included two non-smokers with a
history of chronic asthma who had non-reversible
severe airways obstruction. The remaining 25 of
these 86 patients reversed their FEV1 by 415% and
200ml. The median increase was 270ml, range
210–800, a median 27% FEV1 increase, range
17–87%.
A restrictive disorder (low FEV1 and FVC, with
maintained or elevated FEV1/FVC) was found in five
patients and a further 34 patients had normal
spirometry. Of the six who had never smoked, four
had normal spirograms.Therapies
Medication varied with 61 receiving inhaled corti-
costeroid, 86 short acting b2 agonist, 43 long acting
b2 agonist, 23 ipratropium bromide, three tiotro-
pium. The median dose of inhaled corticosteroid
(betamethasone equivalent) in users was 800 mg,
range 100–2000 mg (Table 1). Of the 23 patients
with COPD and a FEV1o50%, 14 were not on long
acting bronchodilators (b2 agonist or tiotropium),
seven were not on inhaled corticosteroid, (and a
further seven were on inappropriately low doses).
None had undergone a pulmonary rehabilitation
programme.
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Our random sample of 371 general practices with a
response rate of 61% gave us information on
spirometry use in 44% of the practices. This
coverage allows some conclusions to be made
regarding the provision and practice of spirometry.
Over 80% of practices in our sample, had access to
spirometry within their practice and of these,
nearly 90% were using the instrument. This is
greater than previous reports of 39–69% of prac-
tices having spirometers and appears to be a good
response to various guidelines and forthcoming
pressure for general practice services to take on a
primary role in the diagnosis of COPD.10,11
The majority of spirometry usage was by practice
nurses with a modest (30%) usage by general
practitioners. This suggests spirometry is delegated
to nurses and raises issues of training and con-
fidence in the use of this equipment in a staff group
with diverse roles within general practice. This
finding may be reflected in the levels of confidence
reported by the practices with the use spirometry
and the interpretation of the results obtained.
While there appears to be some satisfaction with
58% of practices confident with the performance of
spirometry, 66% reported varying degrees of lack of
confidence with the interpretation of the data
produced.
An explanation of the confidence issue, particu-
larly relating to interpretation, is the great varia-
tion in the time spent on training both in use and
interpretation. This was evidenced by the wide
range of reported training in the use of the
spirometer from none to an estimated 30 h of
training, with a median value of 4 h. Our respon-
dents reported experience suggests less training
had been devoted to interpretation of results with
14% reporting no training, than in the use of the
spirometer where 8% reported no training. Not
surprisingly the most confident practices reported
the greatest amount of training. This reflects a lack
of a recognised training programme with refresher
courses within Wales. Our survey revealed that
training is obtained in a variety of means and there
appears to be no consistent or identifiable standard
with appropriate assessments and review of skills to
ensure a high quality use and interpretation of
spirometry results by any group of health profes-
sionals.
A consequence of the current pattern of use we
found is the wide range of spirometric confirmation
of the diagnosis of COPD. The median of only 37% of
patients having objective confirmation of their
diagnosis seems low, but is greater than the 18%
confirmation of COPD reported in 2000.33 Many
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level, among which the issues we have highlighted
of poor or non-existent training and lack of
confidence in staff carrying out and interpreting
spirometry. Thus, there may be increasing numbers
of spirometers in general practice but there is
under utilisation in the diagnosis of COPD, despite
the published guidelines.9,15 Reversibility testing
was not explored by our questionnaire, but it might
be argued that reversibility testing is not an issue in
view of the low usage of spirometry and the lack of
confidence in the interpretation of the data
generated. These issues might be addressed by
the new contract for general practice, which offers
financial incentives if spirometry is achieved in up
to 90% of the COPD patients within the practice and
spirometry and reversibility achieved in 90% of new
cases. However, without the parallel provision of
adequate training in use and interpretation of
spirometry, and no assessment of the quality of
the data produced, this approach is unlikely to
materially change the current standard of spiro-
metry in general practice, which with appropriate
training, primary care spirometry can be accurate
and valid.34,35
The current state is compounded by the very
limited access to lung function laboratory assess-
ments for most of the practices we surveyed, which
contrasts with reported levels of access of
11–75%.10,11 Such differences may reflect aspects
of geography and previous decisions on health
investment and development of services. Indeed,
much of the respiratory function testing in second-
ary care is carried out in combined cardiorespira-
tory laboratories with only three separately
identified lung function laboratories in Wales. It
may not be appropriate for every practice to
possess a spirometer and trained user, but there
should be provision within an area for sharing a
service between practices, particularly in thinly
populated large geographical areas. We do accept
that a limitation of this study is the self reported
nature of the questionnaire however this was the
only feasible option to encompass the widespread
responses from a large sample of the general
practices.
The consequence of the limited use of spirometry
to confirm the diagnosis of COPD is that 31% of
patients diagnosed with COPD on clinical grounds
did not have evidence of airways obstruction. A 20%
sub-group of patients had reversible airways ob-
struction and were likely to fall into the category of
asthma in view of the magnitude of their FEV1
response. This study reaffirms earlier work suggest-
ing that COPD cannot be reliably diagnosed simply
on clinical grounds in primary care. While objectiveassessment of airways obstruction clarifies not only
COPD but asthma and other respiratory disorders.
Furthermore, in the COPD patients there was a
degree of under prescription of anticholinergic
therapy (15/61), relative over prescription of high
doses of inhaled corticosteroids and a moderate use
of long acting b2 agonists. Whilst airways obstruc-
tion is not the only indicator for prescribing inhaled
corticosteroid or long acting bronchodilator, there
appeared relative lack of use of these in the more
severe groups. After accurate diagnosis of COPD,
attention should be drawn to associated indicators
of severity including exacerbation frequency, ex-
ercise capacity and body mass index in order to
optimise management options including pulmonary
rehabilitation.
This survey of spirometry in general practice
revealed deficits in the use and interpretation of
spirometry, due to low levels of validated training
and a lack of open access to lung function testing
for practices without a spirometer. The introduc-
tion of a new GP contract gives an opportunity to
address the deficits in the diagnosis of COPD in the
UK. In a review of 125 patients with COPD
diagnosed on clinical grounds, a high level of
misdiagnosis of COPD was found and would be
addressed by greater use of spirometry. In view of
the implications of failure to diagnose COPD and
the magnitude of the problem worldwide this study
reinforces the view that more attention needs to
be focussed on COPD patients to ensure accu-
rate diagnosis and implementation of correct
treatment.Acknowledgements
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Thank you to all the practices who took the time to
fill in the questionnaire.Appendix A. Spirometry Questionnaire
1. Do you have access to a spirometer yes/no
If yes, typeyyyHow manyyyy
If no, do you have open access to hospital lung
function, without consultant referral?Yes/No
2. How often is the spirometer used to diagnose
COPD?
Every case/Often/Sometimes/Rarely/Never/N/A
3. Who uses the spirometer?
Practice Nurse/GP/Other (specify)yyyyyy/
N/A
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4. How confident are you with using equipment,
including when to calibrate and informing patient
of the technique?
Happy/limited confidence/Not confident/other-
yyyy
5. How confident are you of interpreting results,
diagnosing respiratory disorders and initiating
treatment based on results?
Happy/limited confidence/Not confident/other-
yyyyyyyyy
6. How much training have you had in total and
who by?
(a) Hours on spirometry training
yyyyyyyy
Who by:- Hospital initiated/Specific course/Drug
company initiative/Otheryyyyy
(b) Hours interpretationyyyyyyyy
Who by:- Hospital initiated/Specific course/Drug
company initiative/Otheryyyyyy
7. Size of practice?yyyyyypatients, y
yyyyyyWTE partners
8. Are you able to give an estimate of number of
COPD patients you haveyyyyyy
9. Roughly how many have been confirmed by
spirometry?yyyyyy
Thank you for your help. If you would like to
know results of this review, please insert e-mail
address hereyyyyyyy
C Bolton P Edwards
Please return to Dr C Bolton, UWCM, Respiratory
Medicine, Llandough Hospital.References
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